CA SB473

Requires health care service plans and health insurance policies issued or renewed on or after January 1, 2023, to cover all available dosage forms and concentrations of at least one insulin product of each insulin type (rapid-acting, short-acting, intermediate-acting, long-acting) with a copayment capped at $35 for a monthly supply, $70 for a 60-day supply, or $105 for a 90-day supply.

Prohibits health care service plans and health insurance policies issued or renewed on or after January 1, 2023, from imposing deductibles, coinsurance, or other cost-sharing requirements on insulin prescriptions covered under the copayment limits, except for the specified copayment amounts.

Prohibits health care service plans and health insurance policies issued or renewed on or after January 1, 2023, from imposing deductible requirements on diabetes management equipment and supplies (blood glucose monitors, test strips, insulin pumps, lancets, syringes, and related items).

Applies to high deductible health plans by exempting certain diabetes management benefits from deductible requirements in accordance with federal Internal Revenue Service rules.

Exempts certain insurance types (vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, disability income) from the requirements.